Natco Pharma falls 5 percent post US court order in favor of Teva


Shares of pharmaceutical company Natco Pharma has slipped 5% to Rs 1,436 on National Stock Exchange (NSE) on reports that the U.S. Supreme Court ruled in favor of Teva over patent for multiple sclerosis drug. “The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product,” a Reuters report said.

Read the source article at Business Standard

About the Author

Leave a Reply